Status:
COMPLETED
Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Introduction: Plasma fibrinogen levels have been identified as an important risk factor for cardiovascular diseases and could have a prognostic value. Bezafibrate decreases fibrinogen levels and also ...
Detailed Description
Patients \>18 years of age who were admitted to the Cardiovascular Intensive Care Unit of the Cardiology Hospital, National Medical Center, Century XXI (Mexico City) and diagnosed with ST segment elev...
Eligibility Criteria
Inclusion
- Patients \>18 years of age who were admitted to the Cardiovascular Intensive Care Unit of the Cardiology Hospital, National Medical Center, Century XXI (Mexico City) and diagnosed with ST segment elevation ACS and hyperfibrinogenemia within 72 h of symptom onset
Exclusion
- Patients with known bezafibrate allergy,
- previous fibrate treatments,
- patients with cardiogenic shock,
- hepatic failure,
- renal failure,
- history of neoplastic disease,
- chronic inflammatory disease or active infectious process,
- anti-inflammatory or immunosuppressive therapies,
- fibrinolysis with streptokinase and
- patients with triglyceride concentrations \>150 mg/dl
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02291796
Start Date
January 1 2011
End Date
December 1 2013
Last Update
November 14 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.